Lercanidipine as a calcium antagonist of the third generation: a review of effectiveness in the hypertension treatment

Abstract

The data from clinical trials that have examined the efficacy and safety of modern third generation calcium antagonist-lercanidipine is presented herein. Results of the following studies demonstrate that treatment with lercanidipine leads to a marked reduction in systolic and diastolic blood pressure without a significant impact on heart rate. Unique pharmacokinetic characteristics of the drug provide its high efficacy and safety, tolerability, convenience, acceptance and high adherence of the said CA in AH patients. Additional lercanidipine properties allow us to recommend the use of this CA in associated pathology cases.

Keywords

• lercanidipine
• lercamen
• dihydropyridines calcium antagonists of the third generation
• randomized clinical trials
• hypertension